An expert discusses the 2025 NCCN guideline updates for ROS1-positive non-small cell lung cancer, highlighting the inclusion of taletrectinib and repotrectinib as preferred first-line therapies due to ...
Nuvalent has said it is on course to file for approval of its ROS1 inhibitor zidesamtinib as a lung cancer treatment, although rival Nuvation Bio has beaten it to market. Cambridge, ...
Repotrectinib achieved a high objective response rate and durable response in the pivotal TRIDENT-1 trial. Repotrectinib is an orally administered tyrosine kinase inhibitor (TKI) that targets ROS1 ...
Ibtrozi (taletrectinib) is approved for ROS1-positive NSCLC, showing high efficacy in TRUST-I and TRUST-II trials. Treatment-naive patients had response rates of 90% and 85%, with significant duration ...
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study Responses were durable with ...
Zidesamtinib achieved a 44% ORR and 1% CR rate in advanced ROS1-positive NSCLC patients previously treated with ROS1 TKIs. The ARROS-1 trial showed zidesamtinib's efficacy, especially in patients with ...
In summary, the study by Lim et al 8 adds another highly effective agent to the growing roster of TKIs for advanced ROS1-positive NSCLC. However, the study also creates a new dilemma in the field, ...
Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy We enrolled 32 patients with advanced NSCLC who tested positive for ROS1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results